1

FQPA Science Review Board (FIFRA SAP Ad hoc) Members Biosketches 

for the April 19-21, 2016

Meeting of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA)

Scientific Advisory Panel (SAP) on Chlorpyrifos: Analysis of Biomonitoring Data

Docket Number: EPA-HQ-OPP-2016-0062

Russell Carr, Ph.D.

Dr. Russell Carr is an Associate Professor in the College of Veterinary Medicine at Mississippi 

State University. He received his B.S. in Biology and Chemistry from Delta State University 

and his M.S. in Zoology and Ph.D. in Animal Physiology from Mississippi State University. Dr. 

Carr has served on multiple US EPA Science Advisory Panels and as a reviewer for

Developmental Neurotoxicology Methods for the National Toxicology Program. His research 

interests are in the area of developmental neurotoxicology with emphasis on agricultural 

pesticides. Using animal models, his current focus is investigating the effects of developmental 

insecticide exposure on long term effects on behavior and matching those effects with changes in 

gene expression and neurochemistry.

Jeff Fisher, Ph.D.

Dr. Jeffrey Fisher is a research toxicologist with the U.S. Food and Drug Administration, 

National Center for Toxicological Research. He was formerly a Professor in the Department of 

Environmental Health Science, College of Public Health at the University of Georgia (UGA). He 

joined the University of Georgia in 2000 and served as Department Head of the Department of 

Environmental Health Sciences from 2000 to 2006 and Director of the Interdisciplinary 

Toxicology Program at UGA from 2006-2010. He spent 25 years at the Toxicology Laboratory, 

Wright Patterson AFB, where he was Principal Investigator and Senior Scientist in the Toxics 

Hazards Division and Technical Advisor for the Operational Toxicology Branch. Dr. Fisher's 

research interests are in the development and application of pharmacokinetic and biologically 

based mathematical models to ascertain health risks from environmental, food-borne and 

occupational chemical exposures. Recently with FDA he has become involved in the use of 

PBPK models for drugs to determine first in dose for infants, evaluate extended release failures 

of generic drugs, and the development of methods to extrapolation from in vitro dissolution 

studies to in vivo pharmacokinetics. Dr. Fisher’s chemical toxicology modeling experience 

includes working with chlorinated and non-chlorinated solvents, fuels, pesticides, perchlorate 

and bisphenol A. He has developed PBPK models for use in cancer risk assessment, estimating 

lactational transfer of solvents, understanding in utero and neonatal dosimetry, quantifying 

metabolism of solvent mixtures and developing biologically motivated models for the 

hypothalamic-pituitary-thyroid axis in rodents and humans. Dr. Fisher has 25 years of 

experience in physiological modeling and has trained several graduate students and postdoctoral 

fellows on the concepts and application of physiological models. He was a Visiting Scientist at 

the Chemical Industry Institute of Toxicology in 1996 and at the NIOSH Taft Laboratory in 

1999. During this time, he also served as Adjunct Professor in the Department of Pharmacology 

and Toxicology at Wright State University. Dr. Fisher has published over 160 papers on 

pharmacokinetics and PBPK modeling in laboratory animals and humans. He has served on 

several national panels and advisory boards for the DoD, ATSDR, USEPA and non-profit 

organizations. He was a U.S. delegate for the North Atlantic Treaty Organization. Dr. Fisher 
2

served on the International Life Sciences Institute Steering Committee, which evaluated 

chloroform and dichloroacetic acid using EPA-proposed Carcinogen Risk Guidelines. He is Past 

President of the Biological Modeling Specialty Section of the Society of Toxicology, reviewer 

for several toxicology journals, and was Co-Principal Investigator on a National Institutes of 

Health (NIH)-supported workshop on Mathematical Modeling at the University of Georgia in the 

fall of 2003. He was a member of the National Academy of Sciences subcommittee on Acute 

Exposure Guideline Levels (AEGLs) from 2004-2010 and Science Advisory Board for the US 

EPA (2007-2010). He is an ad hoc member of the SABs for dioxin and perchlorate. He is a 

fellow of the Academy of Toxicological Sciences and an associate editor for Toxicological 

Sciences. Dr. Fisher has a B.S. degree in biology from the University of Nebraska at Kearney, a 

M.S. degree in biology from Wright State University, and a Ph.D. in Zoology/Toxicology from 

Miami University.

William Funk, Ph.D.

Dr. William Funk is an assistant professor in the Department of Preventive Medicine at 

Northwestern University. In addition to his primary appointment he also serves as faculty in the 

Driskill Graduate Program in Life Sciences, and is an associate member of the Robert H. Lurie 

Comprehensive Cancer Center and a faculty associate in the Institute for Policy Research at 

Northwestern. He received his Ph.D. from the Department of Environmental Sciences and 

Engineering at the University of North Carolina at Chapel Hill in 2009, and has more than 13 

years of experience developing and applying biomarker methods for investigating links between 

the environment and human health. The Funk Laboratory, located in the Robert H. Lurie 

Comprehensive Cancer Center in the Feinberg School of Medicine, is a recently renovated mass 

spectrometry-based laboratory focused on the application of novel methods for estimating 

exposures to environmental toxicants using both targeted and untargeted (i.e. omics) biomarker 

approaches. A primary focus of Dr. Funk’s work is the application of protein adducts as 

exposures biomarkers, with an emphasis on prenatal and pediatric populations. Dr. Funk has 

also helped to pioneer the application of dried blood spot (DBS) sampling as a minimallyinvasive and cost effective alternative to venous blood collection in epidemiological research. In 

addition to his research, Dr. Funk has served as a technical reviewer for the US Environmental 

Protection Agency and the CDC’s National Birth Defects and Prevention Center, and as an ad 

hoc reviewer for the US Department of Justice and the NIH-NIEHS Children’s Environmental 

Health & Disease Prevention Research Center Special Review Panel. Dr. Funk was also a 

member of the National Children’s Study Health Measurement Network ad hoc Biospecimens 

Working Group, and currently serves as a member on the Coronary Artery Risk Development in 

Young Adults Study (CARDIA) Laboratory Subcommittee. Dr. Funk is the director of the 

Environmental Health Science course for the Program in Public Health (PPH) at Northwestern, 

and serves on the PPH’s Executive Committee. Current research in the Funk Laboratory 

includes 1) assessing exposures to toxic metals using DBS sampling methods, 2) quantification 

of cotinine in DBS samples as a biomarker of exposure to environmental tobacco smoke, 3) and 

the application of protein adduct profiles as biomarkers associated with preterm birth, birth 

defects (e.g., congenital heart defects, oral clefts, and hypospadias), multiple myeloma, and 

ovarian cancer. 
3

Panos Georgopoulos, Ph.D.

Dr. Georgopoulos is a Professor of Environmental and Occupational Health at Rutgers 

Biomedical and Health Sciences. Since 1989 he has served on the faculty of Robert Wood 

Johnson Medical School and on the Graduate Faculties of Chemical & Biochemical Engineering, 

Biomedical Engineering, and of Environmental Sciences at Rutgers University. He is a member 

of the Environmental and Occupational Health Sciences Institute (EOHSI) of Rutgers where he 

directs the State-funded Ozone Research Center and the Informatics and Computational 

Toxicology Core for the NIEHS Center for Environmental Exposures and Disease (CEED). Dr. 

Georgopoulos received his M.S. and Ph.D. Degrees in Chemical Engineering from the California 

Institute of Technology (Caltech) and his Dipl. Ing. Degree from the National Technical 

University of Athens. At EOHSI he established and directs the Computational Chemodynamics 

Laboratory (CCL), a state-of-the-art facility for informatics and modeling of complex 

environmental and biological systems. He is also Co-Director of the Environmental 

Bioinformatics and Computational Toxicology Center (ebCTC), a research consortium of 

Rutgers University, Princeton University, and USFDA’s Center for Toxicoinformatics. He 

served as Director of the USDOE-funded Center of Expertise in Exposure Assessment of the 

Consortium for Risk Evaluation with Stakeholder Participation (CRESP). Dr. Georgopoulos has 

participated in both research and teaching in Rutgers graduate programs and has developed 

innovative course materials in modeling and informatics related to environmental health 

applications. He has been the primary doctoral thesis advisor to 22 students, with 14 Ph.D. 

degrees awarded since 1997, and has been mentor to 26 post-doctoral fellows. His research 

interests involve the development and application of mathematical and computational methods 

for diagnostic and mechanistic studies of multipathway physicochemical processes taking place 

in interacting environmental and biological systems. The aim of this research is to improve the 

understanding and quantification of human exposure and biological mechanism-based dosimetry 

and risk for environmental toxics; this is being accomplished through the ongoing development 

of mechanistic multiscale modular computational framework for source-to-dose-to-effect 

modeling of toxicant dynamics. Outcomes of this research include integrative computational 

models of toxicokinetic and toxicodynamic processes at the cellular, tissue and whole body 

levels. Dr. Georgopoulos has lectured as an invited speaker at universities, including the 

Harvard School of Public Health, Johns Hopkins University, Stanford University, Illinois 

Institute of Technology, University of Minnesota, and others. He has published more than 125 

peer-reviewed articles and chapters in scientific journals, books and proceedings, and has 

authored or co-authored several State and Federal Government Documents and numerous 

technical reports. He served on editorial boards of scientific journals and currently serves as 

member of various national and international scientific and technical committees on 

environmental issues, including the USEPA Chemical Safety Advisory Committee.
4

William L. Hayton, Ph.D.

Dr. William L. Hayton is an Emeritus Professor of Pharmacy at The Ohio State University, since 

retirement in 2010. At retirement he was Chair of the Division of Pharmaceutics and he served 

as the Associate Dean for Graduate Studies and Research. His formal training included the BS 

in Pharmacy degree (1967, University of Washington, Seattle), and the Ph.D. degree in 

Pharmaceutics (1971, State University of New York at Buffalo). Dr. Hayton’s expertise is 

pharmacokinetics, particularly construction and validation of mathematical models that describe 

or explain the kinetics of complex biological systems. Dr. Hayton taught Clinical 

Pharmacokinetics to Pharm.D. students and pharmacokinetic/pharmacodynamic (PK/PD) 

modeling to Ph.D. students. Recent research projects were “characterization of the Fc receptormediated transport and catabolism of albumin and IgG in wild type and FcR knockout mice”, 

and the “quantitative PK/PD modeling of the female hypothalamus-pituitary-gonad (HPG) axis 

in the female rainbow trout (Oncorhynchus mykiss)”. The HPG model is based on and integrates 

the biology of gonadotropin, estrogen, androgen and maturational hormone signaling systems, 

and it includes key intermediate steps in the signaling pathways; viz., gonadotropin and sex 

steroid synthesis, hormone receptors and their corresponding mRNA levels. Dr. Hayton’s 

expertise extends to interspecies scaling of pharmacokinetic model parameter values and 

xenobiotic metabolism. Dr. Hayton was a member of the Washington State University College 

of Pharmacy faculty for 19 years before coming to Ohio State in 1990 as Chair of the Division of 

Pharmaceutics. He is author or co-author of more than 100 peer-reviewed scientific 

publications, many of which report on the PK/PD of xenobiotics. He has served as an ad hoc 

member of several FIFRA SAP panels during 2005 - 2014. He has been Principal Investigator 

for peer-reviewed grants from the NIH, NSF, EPA, AFOSR, FDA, and USFWS.

Stella Koutros, Ph.D.

Dr. Koutros received her M.P.H. and Ph.D. in epidemiology from Yale University. She 

completed her doctoral work through the Yale-NCI partnership training program in cancer 

epidemiology, conducting research in the Occupational and Environmental Epidemiology 

Branch (OEEB). In 2008, upon completion of her doctorate she became a fellow in OEEB; she 

was appointed to the position of tenure-track investigator in 2015. Dr. Koutros’s research 

involves the design and conduct of epidemiologic investigations to evaluate occupational 

exposures as potential risk factors for cancer. She employs state-of-the-art exposure assessment 

methods and molecular studies within highly exposed populations to identify and clarify the 

biological mechanisms underlying chemical-induced carcinogenesis. She has a particular 

interest in the interaction between these exposures and inherited genetic variation, also known as 

gene-environment interaction, as well as the interplay between somatic variation and alterations 

at the tumor level and chemical exposures. Dr. Koutros and her collaborators are leading 

investigations in a large cohort of pesticides applicators, the Agricultural Health Study (AHS), to 

evaluate whether pesticide exposure influences cancer risk. In particular, work in the AHS has 

shown an increased risk of aggressive prostate cancer with exposure to specific organophosphate 

insecticides. Dr. Koutros also employs comprehensive information on genetic susceptibility for 

prostate cancer to study the interaction between agricultural pesticide use and cancer risk. Dr. 

Koutros is also currently leading efforts within large case-control studies of bladder cancer to 

identify important occupational exposures that might influence risk, in particular with exposure 

to diesel exhaust. Dr. Koutros and her collaborators are also examining potential geneenvironment interactions as well as incorporating important somatic variation and bladder tumor 
5

marker data to integrate exposure, germline genetic variation, and somatic changes to gain 

insights into the mechanisms of bladder carcinogenesis. Also as co-principal investigator of the 

largest study of acrylonitrile workers in the world, Dr. Koutros is helping to elucidate 

associations with cancer mortality to provide the most powerful epidemiologic evidence 

regarding human carcinogenicity to date.

Isaac Pessah, Ph.D.

Dr. Isaac Pessah obtained his B.S. in Biological Sciences in 1977 from Cornell University and his 

Ph.D. in Toxicology from the University of Maryland College Park in 1984. He was a Postdoctoral 

Fellow at UC Berkeley from 1984 to 1987 during which time he discovered a family of calcium 

channels termed ryanodine receptors. Since then, his research and academic interests have spanned 

the broad area of molecular and cellular mechanisms by which Ca2+ channels regulate cellular 

signaling in muscle, neurons, and immune cells. He studies the organization and function the 

macromolecular complexes regulating ryanodine-sensitive Ca2+ channels and how natural toxin 

derived from marine sponges and scorpions, as well as anthropogenic chemicals of concern to human 

environmental health (e.g. insecticides, rodenticides, and halogenated POPs) promote developmental 

neurotoxicity. Members of his laboratory have been studying gene-environment interactions 

influencing susceptibility that are relevant to autism and related neurodevelopmental disorders using 

humanized mice possessing mutations known to contribute susceptibility to disease. He received the 

Pfizer Award for Research Excellence in 1997 and the Neurobehavioral Toxicology Society’s 

Distinguished Lecture Award in 2010. Dr. Pessah is a member of the UC Davis Superfund Research 

Program, Society of Toxicology and Neurotoxicology Specialty Section, the American Chemical 

Society and Pesticide Toxicology Specialty Section, the American Society for Pharmacology and 

Experimental Therapeutics, the Biophysical Society, and International Neurotoxicology 

Association. He is on the editorial board of several journals. Currently he is Professor of 

Toxicology and in the Department of Molecular Biosciences, and Associate Dean of Research and 

Graduate Education at UC Davis School of Veterinary Medicine. He is Deputy Director of the 

UC Davis Center for Children’s Environmental Health and Disease Prevention. The Center, 

established under his direction in 2000, is a multidisciplinary program aimed at understanding how 

environmental factors influence developmental neurotoxicity. He has served as major advisor to 

over 35 PhD students and postdoctoral fellows and serves on the Executive Committee of two NIH 

predoctoral training programs. He was appointed by Governor Brown to serve on the California 

Developmental and Reproductive Toxicant Identification (DART) Committee. Recently 

Administrator Gina McCarthy appointed him to the US EPA Chemical Assessment Advisory 

Committee.
6

William Popendorf, Ph.D.

Dr. William Popendorf is an emeritus Professor of Industrial Hygiene at Utah State University. 

He served on the Board of the American Industrial Hygiene Association and as a Director of the 

American Board of Industrial Hygiene. Dr. Popendorf taught and conducted research for thirtyfive years, and published over seventy papers and book chapters (culminating in a text book, see 

below). The topics of his research have progressed from pesticide hazards to farm workers in 

1972-1992 to inorganic dusts in agricultural and natural mineral fibers from 1978-1982, organic 

dusts from grains and livestock in 1982-1995, various respiratory hazards in automotive industry 

foundries and metal working fluids in 1987-1994, and broader reviews since 1991 including his 

textbook Industrial Hygiene Control of Airborne Chemical Hazards in 2006. His broad interest 

has been to develop or/and apply predictive models (many developed in other fields) that describe 

how physical mechanisms cause (and can be used to control) the exposures of workers to organic 

vapors, hazardous particulate aerosols, and dermally toxic chemicals, with the expectation that 

such tools will improve the overall practice and knowledge-base of industrial hygiene.

Diane Rohlman, Ph.D.

Dr. Diane Rohlman is an Associate Professor in Occupational and Environmental Health at the 

University of Iowa. Throughout her career she has engaged in both basic and applied research to 

identify, characterize, and prevent occupational and environmental illness and injury in high-risk 

populations. A large part of this research has been with populations living in agricultural 

communities including, immigrant and migrant farmworkers and their families in the US, 

adolescent and adult cotton workers in Egypt, school-age children in Thailand, and a birth cohort 

in the Philippines. Other aspects of her research have focused on the development of health and 

safety interventions, including the development of interventions for agricultural workers and 

young workers. Additionally, she has engaged in a wide range of activities to translate and 

disseminate the products of scientific studies to key stakeholders at local, national and 

international levels. As Director of the graduate training program in agricultural safety and 

health in the Heartland Education and Research Center and Co-PI of the Building Capacity 

project in the Great Plains Center for Agricultural Health, she directs graduate and continuing 

education programs for future and current occupational safety and health specialists. She also led

projects in four other NIOSH funded centers. She is the Director of the Healthier Workforce 

Center, a NIOSH Total Worker Health® Center of Excellence, and Co-PI of the Education and 

Translational Project in the Center, translating scientific findings into resources for small 

businesses. In addition, she leads a project in the Oregon Healthy Workforce Center, another 

NIOSH Total Worker Health® Center, to develop and evaluate an online Total Worker Health 

training for young workers. Furthermore, she is a Co-PI of projects in the National Children’s 

Center for Rural and Agricultural Health and the Pacific Northwest Agricultural Safety and 

Health Center addressing Total Worker Health® topics in agricultural workers. As a member of 

the leadership teams in all of these centers, she is uniquely positioned to serve as Co-PI of the 

Outreach Core in the Great Plains Center.
7

Sharon K. Sagiv, Ph.D., M.P.H.

Dr. Sharon Sagiv is an environmental epidemiologist with research interests focused primarily 

on the impact of early life exposure to environmental toxicants on child development. She 

received her MPH in Epidemiology from Boston University and her doctorate in Epidemiology 

from the University of North Carolina at Chapel Hill. She is currently an Assistant Adjunct 

Professor of Epidemiology at the University of California, Berkeley and an investigator in UC 

Berkeley’s Center for Environmental Research & Children’s Health (CERCH). Dr. Sagiv’s 

research centers around how exposure to environmental toxicants affects fetal and early child 

development with a focus on birth outcomes, childhood obesity and neurodevelopment. Much of 

her work to date is on prenatal exposure to metals and persistent organic pollutants and their 

associations with adverse behavioral development in children, particularly behaviors related to 

attention deficit hyperactivity disorder (ADHD) and she is particularly interested in how 

environmental toxicants impact quantitative, dimensional traits related to ADHD and autism 

spectrum disorders. Dr. Sagiv has served as the Principal Investigator on a number of NIHfunded grants, has served as a mentor for master’s and doctorate students and postdoctoral 

fellows, and has taught classes in epidemiologic methods, environmental epidemiology and grant 

writing. 

Lisa M. Sweeney, Ph.D., DABT, CHMM

Dr. Lisa M. Sweeney is a Senior Scientist with the Henry M. Jackson Foundation for the 

Advancement of Military Medicine, currently on detail to the Naval Medical Research Unit—

Dayton under an Intergovernmental Personnel Act (IPA) assignment. She has a broad range of 

experience in the application of toxicology, chemistry, and engineering to problems in the health 

and environmental sciences. She has over 20 years of experience in risk assessment, 

pharmacokinetics, and biochemical engineering from a variety of private sector and non-profit 

backgrounds. She is an author of over 50 peer-reviewed publications, with over 20 publications 

as first author. Her experience has focused on the development and refinement of 

physiologically-based pharmacokinetic (PBPK) models and their application to risk assessment 

and experimental design. Other risk assessment experience includes preparing toxicological 

reviews and calculating human health risk for children and adults. She currently serves on the 

Society of Toxicology’s Scientific Program Committee as a member and subject matter expert 

on topics pertaining to risk assessment, biological modeling, biomonitoring, regulation, and 

policy. She has previously served on U.S. EPA public peer review panels for the Integrated Risk 

Information System (IRIS) program, evaluated Provisional Peer Reviewed Toxicity Values 

(PPRTVs), and served as an external reviewer for the Agency for Toxic Substances and Disease 

Registry.
8

Alvin Terry Jr., Ph.D.

Dr. Alvin V. Terry Jr. is Associate Vice President for Basic Science Research at Augusta 

University, Augusta Georgia. He is also is a tenured Regents Professor and the Chair of the 

Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University. 

He also holds joint appointments as Professor of Neurology and Graduate Studies at Augusta 

University, and is a licensed pharmacist in Georgia and South Carolina. A native of South 

Carolina, Dr. Terry received a B.S. in Pharmacy from the Medical University of South Carolina, 

Charleston, S.C. in 1982 and a Ph.D. in Pharmacology from the University of South Carolina, 

Columbia, S.C. in 1991. He received post-doctoral training and served as a junior faculty 

member at the Medical College of Georgia (MCG) from 1991-1994, then served as a faculty 

member of the University of Georgia, College of Pharmacy from 1994 until re-joining the 

Department of Pharmacology and Toxicology at MCG as Professor in December of 2005. To 

date, Dr. Terry has published 151 peer-reviewed research articles, 8 book chapters, and holds 1 

US patent. His research is currently supported by the National Institutes of Health (NIH), the 

Department of Defense (DOD), and the pharmaceutical industry. Dr. Terry has served on 

multiple study sections for a variety of governmental agencies including The National Institutes 

of Health, NASA and The Department of Veterans Affairs, and The Department of Defense. He 

is a member of the Editorial Advisory Board of the Journal of Pharmacology and Experimental 

Therapeutics and he has also previously served as a consultant for an Environmental Protection 

Agency Federal Insecticide, Fungicide and Rodenticide Act Scientific Advisory Panel. 

Dr. Terry's research interests focus on the role of central acetylcholine (i.e., cholinergic) 

pathways in cognition; specifically how these neuronal pathways are involved in the memory 

dysfunction associated with neuropsychiatric illnesses and exposures to environmental toxins, 

especially organophosphates. The actions of both pharmaceutical and toxicological agents on the 

cholinergic neuronal system, axonal transport, as well as the major growth factors (nerve growth 

factor, brain derived growth factor) that support the cholinergic system are of particular interest. 

His laboratory also focuses on drug discovery and development strategies for the treatment of 

disorders of cognition. The laboratory employs a variety of methods to test hypotheses ranging 

from behavioral testing in animal models (rodents to non-human primates) to molecular, cellular 

and analytical techniques.